WallStreetZenWallStreetZen

NASDAQ: RPRX
Royalty Pharma PLC Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

RPRX past earnings growth

How has RPRX's earnings growth performed historically?
Company
-48.11%
Industry
8.82%
Market
36.61%
RPRX's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
RPRX's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance

RPRX past revenue growth

How has RPRX's revenue growth performed historically?
Company
4.51%
Industry
100.74%
Market
13.73%
RPRX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
RPRX's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
RPRX's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

RPRX earnings and revenue history

Current Revenue
$2.4B
Current Earnings
$254.9M
Current Profit Margin
10.8%

RPRX Return on Equity

Current Company
2.6%
Current Industry
1.4%
Current Market
22.1%
RPRX's Return on Equity (2.6%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when RPRX announces earnings.

RPRX Return on Assets

Current Company
1.5%
Current Industry
-1.3%
RPRX is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

RPRX Return on Capital Employed

Current Company
2.78%
Current Industry
12.1%
RPRX's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

RPRX vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
RPRX$2.36B$442.78M$254.95M+60.48%-53.00%
BMRN$2.23B$225.06M$99.99M+9.20%-62.69%
INCY$3.51B$635.51M$366.49M+15.23%+3.30%
BGNE$1.81B-$1.67B-$1.73B+41.10%N/A
LEGN$164.66MN/A-$532.06M+117.31%N/A
View Top Biotech Stocks

RPRX earnings dates

Next earnings date
Nov 6, 2023

Royalty Pharma Earnings & Revenue FAQ

What were RPRX's earnings last quarter?

On Invalid Date, Royalty Pharma (NASDAQ: RPRX) reported Q2 2023 earnings per share (EPS) of $0.51, up 27.14% year over year. Total Royalty Pharma earnings for the quarter were $227.63 million. In the same quarter last year, Royalty Pharma's earnings per share (EPS) was $0.70.

If you're new to stock investing, here's how to buy Royalty Pharma stock.

What was RPRX's earnings growth in the past year?

As of Q3 2023, Royalty Pharma's earnings has grown -48.11% year over year. This is 56.93 percentage points lower than the US Biotechnology industry earnings growth rate of 8.82%. Royalty Pharma's earnings in the past year totalled $254.95 million.

What is RPRX's earnings date?

Royalty Pharma's earnings date is Invalid Date. Add RPRX to your watchlist to be reminded of RPRX's next earnings announcement.

What was RPRX's revenue last quarter?

On Invalid Date, Royalty Pharma (NASDAQ: RPRX) reported Q2 2023 revenue of $538.20 million up 0.42% year over year. In the same quarter last year, Royalty Pharma's revenue was $535.96 million.

What was RPRX's revenue growth in the past year?

As of Q3 2023, Royalty Pharma's revenue has grown 4.51% year over year. This is 96.23 percentage points lower than the US Biotechnology industry revenue growth rate of 100.74%. Royalty Pharma's revenue in the past year totalled $2.36 billion.
©2023 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.